J. Safra Sarasin Holding Ag Viridian Therapeutics, Inc.\De Transaction History
J. Safra Sarasin Holding Ag
- $5.52 Trillion
- Q1 2025
A detailed history of J. Safra Sarasin Holding Ag transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, J. Safra Sarasin Holding Ag holds 72,672 shares of VRDN stock, worth $1.06 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
72,672
Previous 36,453
99.36%
Holding current value
$1.06 Million
Previous $699 Million
40.19%
% of portfolio
0.02%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding VRDN
# of Institutions
189Shares Held
79.6MCall Options Held
92.2KPut Options Held
55.2K-
Deep Track Capital, LP Greenwich, CT5.38MShares$78.7 Million2.54% of portfolio
-
Black Rock Inc. New York, NY4.77MShares$69.8 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ4.7MShares$68.8 Million5.34% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.56MShares$66.8 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$56.8 Million12.64% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $584M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...